Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals EVP and Chief Business Officer Joseph Baroldi reported a mix of option exercises and share sales in Ionis stock. In early March 2026, he and his spouse exercised non-qualified stock options into common stock and then sold a net 6,659 shares, including 4,096 directly owned shares at $79.36 per share.
Additional indirect sales by his spouse involved smaller blocks such as 2,088 shares at $80.4079 and 36 shares at $81.01, alongside option-related acquisitions at exercise prices of $32.60 and $56.78. Footnotes state that these sales were made under Rule 10b5-1 trading plans adopted by Baroldi and his spouse.
IONS amended a Form 144 filing reporting secondary sales of common stock by Frank Bennett. The amendment lists sales of $684,264 for 8,977 shares on 01/16/2026 and $487,898 for 5,885 shares on 01/30/2026.
The filing also lists securities available to be sold including 65,089 shares tied to an option exercise (grant date 01/03/2022) and 20,000 restricted stock units (grant date 01/15/2017), as shown in the "Securities To Be Sold" section.
IONS reported a Form 144 notice proposing sales of common stock by an insider. The filing lists 8,198 shares associated with Stifel Nicolaus and shows an option‑related amount of 7,773 shares with a 03/03/2026 date. The filing also records 1,171 shares sold in the past three months by Mariana Baroldi on 03/03/2026.
Joseph Baroldi filed a Form 144 to sell Common Stock. The filing lists 4,096 shares of Common Stock tied to Restricted Stock Units (grant date 01/15/2022) and identifies Stifel Nicolaus & Company Inc. as the broker for the proposed sale dated 03/03/2026. The filing also shows recent dispositions, including sales of 5,296 shares on 01/30/2026 and 6,999 shares on 01/16/2026, with associated aggregate amounts listed in the excerpt.
IONS submitted a Form 144 notice reporting proposed sales of Common Stock. The excerpt lists numeric entries 5,035,928.00 and 161,970,000 with an explicit date of 03/03/2026 and identifies the market as Nasdaq. The filing itemizes common stock tied to an Option Exercise (07/01/2018) and Restricted Stock Units (07/15/2021).
IONS filed a Form 144 reporting proposed sales of Common Stock by an affiliate. The filing lists securities tied to option exercises dated 01/02/2024, 01/03/2023, and 01/03/2022 with quantities 10,461, 4,145, and 5,500, and Restricted Stock Units dated 01/13/2024 totaling 15,937 shares.
The filing also discloses recent sales by Shannon Devers: 44,199 shares on 01/07/2026 ($3,756,915.00), 8,353 shares on 01/16/2026 ($636,626.00), and 3,977 shares on 01/22/2026 ($323,490.00).
Ionis Pharmaceuticals EVP Research Eric Swayze reported an employee stock purchase plan transaction in Ionis common stock. On February 27, 2026, he acquired 256 shares under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan at an average price of $48.8665 per share. These plan shares may not be sold until August 27, 2026. After this transaction, he directly held 32,361 common shares. A separate line also shows 318 shares held indirectly by his son.
Ionis Pharmaceuticals executive Patrick R. O'Neil acquired additional common shares through an employee stock purchase plan. On February 27, 2026, he purchased 376 shares of Ionis common stock at an average price of $48.8665 per share under the Amended and Restated 2000 Employee Stock Purchase Plan. Following this transaction, his direct holdings increased to 72,359 common shares, and the newly purchased shares cannot be sold until August 27, 2026.
IONIS PHARMACEUTICALS INC CEO Brett P. Monia acquired 484 shares of common stock on February 27, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $48.8665 per share. After this transaction, the CEO directly owns 254,981 shares. These shares may not be sold until August 27, 2026.